Lubmed Dobroslaw Lubarski Radoslaw Naumowicz Sp. j.
- Address
- Ul. Jana III Sobieskiego 50, 62-030 Luboń, Poland
Bacterial Infections and Mycoses
The research conducted at Lubmed Dobroslaw Lubarski Radoslaw Naumowicz Sp. j. concentrates on meningococcal disease, testing novel conjugate vaccine strategies in infants and toddlers to determine safety, reactogenicity, and the strength of the immune response.
- Immunogenicity assessment of meningococcal vaccine candidates
- Safety and reactogenicity evaluation in young children
- Comparison of different vaccine formulations across serogroups A, C, W, Y and B
- Measurement of serogroup‑specific antibody titers
With a total of three trials and a single dedicated investigator, the site is advancing preventive options for bacterial infections, aiming to protect healthy volunteers and reduce the burden of meningococcal infections.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 1 of 2 therapeutic areas and 15 of 27 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Pfizer Inc.1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Lubmed Dobroslaw Lubarski Radoslaw Naumowicz Sp. j.
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of Safety, Tolerability, and Immunogenicity of MenABCWY-2nd Gen Vaccine in Healthy Infants with Meningococcal Infections | GlaxoSmithKline Biologicals | Phase I | Not Recruiting | Nov 2021 | Nov 2025 |
IMP list
lock Showing 1 of 27 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| N. Meningitidis Group C (Strain C11) Polysaccharide (De-O-Acetylated) Conjugated To Tetanus Toxoid | 2 | Unknown | 2021-11-29 | 2024-03-12 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.